Catalent has announced plans to acquire Cook Pharmica for $950m.

The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.

Both the acquirer and target entities are pharmaceutical companies based in the US.

"Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m."

Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m.

The acquisition will strengthen the company’s business and help in accelerating the development of its therapeutics.

Both companies involved in the acquisition are based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now